The agreement gives Pharmanovia exclusive manufacturing, development and commercialization rights across 66 countries as IMPACT prepares for a potential European approval in the second half of 2026.
IMPACT Therapeutics said it entered an exclusive partnership with Pharmanovia that grants the specialty pharmaceutical company rights to manufacture, develop and commercialize Senaparib across Europe, the Middle East and North Africa, Australia and New Zealand for maintenance monotherapy in advanced high-grade epithelial ovarian, fallopian tube and primary peritoneal cancer. The deal can deliver up to 423.5 million euros to IMPACT through an upfront payment, near-term regulatory milestones and commercial milestones tied to sales thresholds, plus tiered royalties reaching the mid-twenties percent of net sales. The company said the partnership expands Senaparib’s global footprint to 66 countries and marks its first step in bringing its validated treatment options to patients outside China. Senaparib is a PARP1/2 inhibitor (targeted DNA-repair blocking cancer drug) developed by IMPACT. Its European MAA (marketing authorization application) was formally accepted by the EMA (European Medicines Agency) in August 2025, with approval expected in the second half of 2026.